Regarding lipid profiles in patients receiving tirzepatide or semaglutide in the SURPASS-2 trial, there were reductions in triglycerides that were greater with tirzepatide than semaglutide, as well as improvements in high-density lipoprotein cholesterol and significant reductions in very low-density lipoprotein cholesterol
Proton-pump inhibitors (e.g., omeprazole, esomeprazole, and lansoprazole), used to treat Zollinger-Ellison syndrome and gastroesophageal reflux disease (GERD), markedly decrease stomach acid secretion required for the release of vitamin B 12 from food but not from supplements
The development represented an important stabilization point for the GLP-1 market after prolonged supply constraints caused by unprecedented demand for obesity and diabetes treatments In February 2025, the U.S
Targeted Supplement Support : My patients experience significantly fewer side effects when supplementing with a specific protocol of digestive enzymes, ginger, and gut-healing nutrients
